Clinical trials for chronic kidney disease in Scotland

Research into three potential new medicines which can slow down the progress of chronic kidney disease and reduce the risk that patients require a transplant or dialysis will be backed by a new investment from AstraZeneca.  The Scottish Government said a "triple helix" partnership between the pharmaceutical giant, NHS Scotland, and researchers based at the universities of Glasgow and Dundee will help to accelerate clinical trials into the disease.